Patents by Inventor Denise Thurber

Denise Thurber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Coding sequences of the human BRCA1 gene
    Publication number: 20030022184
    Abstract: This invention is directed to the isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1(omi1), BRCA1(omi2), and BRCA1(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences. This invention is further related to protein therapy with BRCA1(omi) proteins or their functional equivalent.
    Type: Application
    Filed: October 22, 2001
    Publication date: January 30, 2003
    Applicant: OncorMed. Inc.
    Inventors: Patricia D. Murphy, Antonette C.P. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise Thurber, Bin Zeng
  • Coding sequences of the human BRCA1 gene
    Patent number: 6130322
    Abstract: This invention is directed to the isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1.sup.(omi1), BRCA1.sup.(omi2), and BRCA1.sup.(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences. This invention is further related to protein therapy with BRCA.sup.(omi) proteins or their functional equivalent.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: October 10, 2000
    Assignee: Gene Logic, Inc.
    Inventors: Patricia D. Murphy, Antonette C. P. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise Thurber, Bin Zeng